Awakn Life Sciences Corp
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavi… Read more
Market Cap & Net Worth: Awakn Life Sciences Corp (AWKNF)
Awakn Life Sciences Corp (PINK:AWKNF) has a market capitalization of $2.71 Million ($2.71 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #33734 globally and #11017 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Awakn Life Sciences Corp's stock price $0.07 by its total outstanding shares 41662600 (41.66 Million).
Awakn Life Sciences Corp Market Cap History: 2025 to 2025
Awakn Life Sciences Corp's market capitalization history from 2025 to 2025. Data shows growth from $2.71 Million to $2.71 Million (0.00% CAGR).
Awakn Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Awakn Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AWKNF by Market Capitalization
Companies near Awakn Life Sciences Corp in the global market cap rankings as of March 19, 2026.
Key companies related to Awakn Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Awakn Life Sciences Corp Historical Marketcap From 2025 to 2025
Between 2025 and today, Awakn Life Sciences Corp's market cap moved from $2.71 Million to $ 2.71 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Awakn Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.71 Million USD |
| MoneyControl | $2.71 Million USD |
| MarketWatch | $2.71 Million USD |
| marketcap.company | $2.71 Million USD |
| Reuters | $2.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.